Vimta Labs: First biologics order lands in Q1FY27, margins hold at 36.4% (NSE: VIMTALABS)
Vimta Labs (NSE: VIMTALABS) filed Q1FY27 results on 2026-07-20 showing total income of ₹1,129 Mn, up 13.7% YoY, with EBITDA margin at 36.4% (up 70 bps YoY, down 120 bps QoQ). The same filing disclosed that its biologics contract research and development services (CRADS) had commenced, and the subsequent concall on 2026-07-24 confirmed the company's first biologics order — entry into what management called the "high-growth life sciences CRAD" segment.
Q4FY26 filing: entering biologics, setting targets
Vimta's Q4FY26 results, filed on 2026-05-06, showed revenue of ₹112 Cr, up 16.6% YoY, with EBITDA margin at 37.6%. The same filing announced entry into biologics contract research and disclosed management targets: 20-25% CAGR and a ₹500 Cr annualized run-rate. PAT for the quarter was ₹210 Mn, up 11.4% YoY, per the Q1FY27 filing on 2026-07-20.
Q1FY27: first order, margin nuance
The Q1FY27 filing (2026-07-20) showed revenue growth of 13.7% YoY, decelerating from Q4's 16.6% pace. EBITDA margin at 36.4% expanded 70 bps YoY but contracted 120 bps sequentially. The concall on 2026-07-24 added detail: gross margin contracted 150 bps YoY, snapping a long margin-expansion streak, as input-cost inflation ran ahead of revenue growth. The same call confirmed the first biologics order had been secured and that CRADS had commenced.
Credit rating: reaffirmed, facility trimmed
On 2026-09-02, CARE Ratings reaffirmed Vimta's long-term bank facility rating at 'CARE A; Stable' and short-term at 'CARE A1'. The total rated amount is ₹61.28 Cr. The long-term bank facility amount was reduced from ₹37.67 Cr to ₹25.50 Cr in the rating note.
What the filings say comes next
The Q4FY26 filing (2026-05-06) disclosed management's stated targets of 20-25% CAGR and a ₹500 Cr annualized run-rate, without a time-bound period. The Q1FY27 filings (2026-07-20 and 2026-07-24) confirm the biologics CRADS segment is operational with a first order in hand; no further numerical targets were disclosed in those filings.
Alpha Inflection is research infrastructure, not investment advice. We are not SEBI-registered investment advisers. Everything above is compiled from public corporate filings, with sources cited. Do your own research.
The filing evidence
| Date | What the filing said | Detail | Source |
|---|---|---|---|
| 20 Jul 2026 | Vimta Labs Q1FY27: Revenue ₹109.1 Cr (+11.8% YoY), EBITDA margin 37.7% (+140bps YoY); steady start with margin expansion, though growth decelerates from H2FY25 pace. | filing | |
| 20 Jul 2026 | Q1 FY27 total income ₹1,129 Mn, +13.7% YoY; EBITDA margin 36.4% (+70 bps YoY, -120 bps QoQ); PAT ₹210 Mn, +11.4% YoY; biologics CRADS commenced | filing | |
| 6 May 2026 | Vimta Labs reports Q4FY26 revenue of ₹112 Cr (+16.6% YoY), EBITDA margin of 37.6%, and enters biologics contract research; targets 20-25% CAGR and ₹500 Cr annualized run-rate. | ||
| 20 Jul 2026 | Q1FY27 revenue ₹109.1 Cr up 11.8% YoY, PAT up 11.4% YoY; gross margin contracts 150bps YoY snapping a long margin-expansion streak, as input-cost inflation outpaces revenue growth. | filing | |
| 24 Jul 2026 | Vimta Labs reports steady Q1FY27 with 13.7% YoY revenue growth and secures first Biologics order, marking entry into high-growth life sciences CRAD | filing | |
| 2 Sept 2026 | CARE Ratings reaffirms Vimta Labs' long-term and short-term bank facility ratings at 'CARE A; Stable / CARE A1'. | CARE Ratings has reaffirmed Vimta Labs' credit ratings for its bank facilities: long-term facilities at 'CARE A; Stable' and short-term facilities at 'CARE A1'. The total rated amount is ₹61.28 crore, with the long-term bank facility amount reduced from ₹37.67 crore to ₹25.50 crore. | filing |
Quick answers
- What did Vimta Labs disclose?
- Vimta Labs (NSE: VIMTALABS) filed Q1FY27 results on 2026-07-20 showing total income of ₹1,129 Mn, up 13.7% YoY, with EBITDA margin at 36.4% (up 70 bps YoY, down 120 bps QoQ).
- What are the key numbers?
- Vimta's Q4FY26 results, filed on 2026-05-06, showed revenue of ₹112 Cr, up 16.6% YoY, with EBITDA margin at 37.6%. The same filing announced entry into biologics contract research and disclosed management targets: 20-25% CAGR and a ₹500 Cr annualized run-rate. PAT for the quarter was ₹210 Mn, up 11.4% YoY, per the Q1FY27 filing on 2026-07-20.
- What does Vimta Labs say comes next?
- The Q4FY26 filing (2026-05-06) disclosed management's stated targets of 20-25% CAGR and a ₹500 Cr annualized run-rate, without a time-bound period. The Q1FY27 filings (2026-07-20 and 2026-07-24) confirm the biologics CRADS segment is operational with a first order in hand; no further numerical targets were disclosed in those filings.
Research and educational content only. Not investment advice. Drafted from regulatory filings and published automatically — see our editorial policy.